Literature DB >> 22647759

Liver fibrosis: a bidirectional model of fibrogenesis and resolution.

P Ramachandran1, J P Iredale.   

Abstract

Liver fibrosis is the generic response to chronic injury of varying aetiologies. A number of common mechanisms link this response to the pathogenesis of fibrosis in other organs. While long thought to be relentlessly progressive, there is now excellent evidence in both human liver disease and animal models that hepatic fibrosis is potentially reversible. The liver therefore provides an excellent bidirectional model for the study of fibrogenesis and fibrosis resolution. In this article, we will review the evidence for the reversibility of liver fibrosis. We will highlight some of the mechanisms responsible for fibrogenesis and fibrosis regression, focussing on the role of hepatic myofibroblast activation and apoptosis, the importance of matrix metalloproteinases and their tissue inhibitors and the central involvement of hepatic macrophages in orchestrating this process. Finally, we will briefly discuss what renders liver fibrosis irreversible and how this accumulating knowledge base could lead to badly needed anti-fibrotic therapies in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22647759      PMCID: PMC3424469          DOI: 10.1093/qjmed/hcs069

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  25 in total

1.  Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration.

Authors:  Razao Issa; Xiaoying Zhou; Nathan Trim; Harry Millward-Sadler; Stephen Krane; Christopher Benyon; John Iredale
Journal:  FASEB J       Date:  2002-11-15       Impact factor: 5.191

2.  Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors.

Authors:  R Issa; E Williams; N Trim; T Kendall; M J Arthur; J Reichen; R C Benyon; J P Iredale
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

3.  Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse.

Authors:  Hitoshi Yoshiji; Shigeki Kuriyama; Junichi Yoshii; Yasuhide Ikenaka; Ryuichi Noguchi; Toshiya Nakatani; Hirohisa Tsujinoue; Koji Yanase; Tadashi Namisaki; Hiroo Imazu; Hiroshi Fukui
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

4.  Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function.

Authors:  James A Thomas; Caroline Pope; Davina Wojtacha; Andrew J Robson; Timothy T Gordon-Walker; Stephen Hartland; Prakash Ramachandran; Marielle Van Deemter; David A Hume; John P Iredale; Stuart J Forbes
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

Review 5.  Macrophages: master regulators of inflammation and fibrosis.

Authors:  Thomas A Wynn; Luke Barron
Journal:  Semin Liver Dis       Date:  2010-07-21       Impact factor: 6.115

Review 6.  Reversibility of liver fibrosis.

Authors:  Prakash Ramachandran; John P Iredale
Journal:  Ann Hepatol       Date:  2009 Oct-Dec       Impact factor: 2.400

Review 7.  Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair.

Authors:  John Iredale
Journal:  Pharmacol Res       Date:  2008-07-04       Impact factor: 7.658

Review 8.  Exploring the full spectrum of macrophage activation.

Authors:  David M Mosser; Justin P Edwards
Journal:  Nat Rev Immunol       Date:  2008-12       Impact factor: 53.106

9.  Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis.

Authors:  Karlin Raja Karlmark; Ralf Weiskirchen; Henning W Zimmermann; Nikolaus Gassler; Florent Ginhoux; Christian Weber; Miriam Merad; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

10.  High-dose enalapril treatment reverses myocardial fibrosis in experimental uremic cardiomyopathy.

Authors:  Karin Tyralla; Marcin Adamczak; Kerstin Benz; Valentina Campean; Marie-Luise Gross; Karl F Hilgers; Eberhard Ritz; Kerstin Amann
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

View more
  38 in total

1.  Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis.

Authors:  Mark A Barnes; Megan R McMullen; Sanjoy Roychowdhury; Nabil Z Madhun; Kathryn Niese; Mitchell A Olman; Abram B Stavitsky; Richard Bucala; Laura E Nagy
Journal:  J Leukoc Biol       Date:  2014-11-14       Impact factor: 4.962

2.  Macrophage autophagy protects against liver fibrosis in mice.

Authors:  Jasper Lodder; Timothé Denaës; Marie-Noële Chobert; JingHong Wan; Jamel El-Benna; Jean-Michel Pawlotsky; Sophie Lotersztajn; Fatima Teixeira-Clerc
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

3.  An ω-3-enriched diet alone does not attenuate CCl4-induced hepatic fibrosis.

Authors:  Todd R Harris; Sean Kodani; Jun Yang; Denise M Imai; Bruce D Hammock
Journal:  J Nutr Biochem       Date:  2016-09-14       Impact factor: 6.048

Review 4.  The balancing act of the liver: tissue regeneration versus fibrosis.

Authors:  Lucía Cordero-Espinoza; Meritxell Huch
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

Review 5.  The use of marine-derived bioactive compounds as potential hepatoprotective agents.

Authors:  Dileep G Nair; Ralf Weiskirchen; Salma K Al-Musharafi
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

6.  Transient receptor potential vanilloid 4 inhibits rat HSC-T6 apoptosis through induction of autophagy.

Authors:  Lei Zhan; Yang Yang; Tao-Tao Ma; Cheng Huang; Xiao-Ming Meng; Lei Zhang; Jun Li
Journal:  Mol Cell Biochem       Date:  2015-01-20       Impact factor: 3.396

Review 7.  Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review.

Authors:  Giuseppina Palladini; Andrea Ferrigno; Plinio Richelmi; Stefano Perlini; Mariapia Vairetti
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 8.  Physiological and pathological impact of exosomes of adipose tissue.

Authors:  Yan Zhang; Mei Yu; Weidong Tian
Journal:  Cell Prolif       Date:  2016-01-18       Impact factor: 6.831

9.  Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study.

Authors:  Audrey L French; Jonathan W Martin; Charlesnika T Evans; Marion Peters; Seble G Kessaye; Marek Nowicki; Mark Kuniholm; Elizabeth Golub; Michael Augenbraun; Seema N Desai
Journal:  J Acquir Immune Defic Syndr       Date:  2017-12-01       Impact factor: 3.731

10.  Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model.

Authors:  Florian P Reiter; Ralf Wimmer; Lena Wottke; Renate Artmann; Jutta M Nagel; Manuel O Carranza; Doris Mayr; Christian Rust; Peter Fickert; Michael Trauner; Alexander L Gerbes; Simon Hohenester; Gerald U Denk
Journal:  World J Hepatol       Date:  2016-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.